LILLY ANNOUNCES LAYOFFS AFTER DRUG TRIAL FAILS

Lilly USA announced Thursday it will eliminate about 485 jobs after the failure of a drug intended to treat Alzheimer’s disease. Eli Lilly’s stock price closed down 69 cents Thursday to $ 76.84. In December, Lilly announced that trials of solanezumab showed the drug did not achieve its goal.